Monoclonal antibody (mAb) therapies, although widely established in cancer treatment, are increasingly being developed and repurposed for the long term management of chronic autoimmune and inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. Many of these conditions disproportionately affect women, raising important questions about fetal...
Acute myeloid leukemia (AML) is an aggressive blood cancer driven by genetic and epigenetic alterations that disrupt normal hematopoiesis. Among these, the H3K27M mutation, originally identified in pediatric high-grade gliomas, reshapes gene repression programs by reducing global H3K27 trimethylation. Although rare, H3K27M mutations have been detected in preleukemic hematopoietic stem cells...
Hematopoietic stem cell (HSC) maintenance depends on the regulation of ribosome function. Mutations in ribosome-associated genes disrupt this regulation, leading to congenital disorders characterized by anemia, bone marrow failure, and an increased risk of hematologic malignancies. These pathologies are associated with the activation of the p53 stress response arising through ribosomal...
The dynamics of malignant neoplasms of the central nervous system, such as malignant gliomas and brain metastases, are strongly shaped by the blood–brain barrier and by interactions between tumor cells and immune populations within the tumor microenvironment. In particular, tumor-associated myeloid populations—including microglia and macrophages—can promote tumor growth through...
This session will bring together leading researchers to discuss quantitative methods for studying immune-related therapies and tumor-specific mechanisms in cancer to support the development of more effective treatments. Our objective is to highlight immune-focused treatments and models and their significance to cancer research, from immune-mediated treatment optimization, mechanisms underlying...
